Baxdrostat and the New Frontier in Resistant Hypertension

Dr. Elena Rodriguez

You have a patient, um, sitting in front of you taking three, sometimes four different daily blood pressure pills, right? An ACE inhibitor, a calcium channel blocker, a diuretic... and yet, their systolic blood pressure is still, uh, stubbornly stuck above 140 millimeters of mercury.

Dr. James Whitfield

It is, uh, genuinely one of the most frustrating scenarios in clinic. We call it resistant hypertension, and so often the hidden driver behind it is aldosterone. The adrenal glands keep churning it out, and it forces the kidneys to hold onto sodium, pulls in water, stiffens the arteries, and blood pressure just will not budge.

Dr. Elena Rodriguez

Right! But for decades, stopping aldosterone at the actual enzymatic source was basically considered a pharmacological dead end. And, and the reason why is down to basic molecular structure. The enzyme that makes aldosterone, which is called CYP11B2, or aldosterone synthase... it shares 93 percent of its sequence identity with CYP11B1.

Dr. James Whitfield

Ninety three percent. That is... I mean, that is almost identical.

Dr. Elena Rodriguez

It is essentially a structural twin. And CYP11B1 is the enzyme that makes cortisol. So if you tried to block the aldosterone enzyme, early drug candidates almost always shut down cortisol production too, which leads to life threatening adrenal insufficiency. You solved one problem only to trigger a metabolic crisis.

Dr. James Whitfield

Which is why clinically, we were forced to settle for downstream receptor blockers, like spironolactone or eplerenone. We could only block the receptor, not stop the hormone from being produced in the first place.

Dr. Elena Rodriguez

Exactly. Until now. This new molecule, baxdrostat, achieves over a 100 fold selectivity for CYP11B2 over CYP11B1. It manages to target the exact pockets that distinguish the aldosterone enzyme from the cortisol enzyme. So it turns off aldosterone synthesis right at the adrenal cortex without suppressing cortisol at all.

Dr. James Whitfield

From a bedside perspective, Elena, that shift is huge. Mineralocorticoid receptor antagonists like spironolactone are great drugs, but off target binding causes real issues. With spironolactone, men frequently develop painful gynecomastia, or women get menstrual irregularities. And many patients just drop the medication entirely. So having a targeted selective inhibitor that shuts down production at the source, um, that changes the whole therapeutic conversation.

Dr. Elena Rodriguez

And that brings us straight to the Phase 3 BaxHTN trial results that were just published in the New England Journal of Medicine. They evaluated baxdrostat in 794 randomized patients who had uncontrolled or resistant hypertension. All of them had a seated systolic blood pressure between 140 and 170 millimeters of mercury, despite already taking stable doses of two or three or more antihypertensive medications, including a diuretic.

Dr. James Whitfield

A very typical resistant hypertension cohort. They randomized them to receive either 1 milligram of baxdrostat, 2 milligrams, or placebo once daily for 12 weeks, right?

Dr. Elena Rodriguez

Yes! And looking at the primary outcome, at 12 weeks, the change from baseline in the least squares mean seated systolic blood pressure was remarkable. Seated systolic blood pressure fell by 14.5 millimeters of mercury in the 1 milligram group, and 15.7 millimeters of mercury in the 2 milligram group, compared to just 5.8 millimeters of mercury with placebo.

Dr. James Whitfield

So after adjusting for placebo, you are seeing net reductions of 8.7 millimeters of mercury for the 1 milligram dose and 9.8 millimeters of mercury for the 2 milligram dose. P values less than 0.001. In patients who were already on three drugs, dropping systolic pressure by nearly 10 additional millimeters of mercury... that is a massive clinical effect.

Dr. Elena Rodriguez

It really is. But, um, we have to talk about the biochemical tradeoff here. Because even when you selectively inhibit aldosterone production without touching cortisol, aldosterone still plays a critical role in renal potassium excretion. If you turn off aldosterone, the kidneys hold onto potassium.

Dr. James Whitfield

Right, hyperkalemia. Did they see significant spikes in serum potassium during the 12 weeks?

Dr. Elena Rodriguez

They did. Severe hyperkalemia, defined as potassium levels greater than 6.0 millimoles per liter, occurred in 3.0 percent of patients in the 2 milligram baxdrostat group, compared to only 0.4 percent in the placebo group. It proves that even with exquisite enzymatic selectivity, the downstream physiological effect on renal potassium handling remains a real constraint.

Dr. James Whitfield

That three percent signal means potassium monitoring will be mandatory if this reaches clinical practice. But, uh, let us also keep the long view in mind. A 10 millimeter drop in systolic blood pressure at 12 weeks is a fantastic surrogate marker, a clear biomarker victory. But a surrogate outcome is not a clinical outcome.

Dr. Elena Rodriguez

Exactly. Twelve weeks of lowered blood pressure tells us the biology works, but it does not tell us yet whether baxdrostat reduces hard clinical endpoints like strokes, myocardial infarctions, or progression to end stage kidney disease over five or ten years.

Dr. James Whitfield

Precisely. Selective aldosterone synthase inhibition is a huge leap forward in translational biochemistry, but we will need those long term outcome trials before we know its true place in care. Good talking through the data, Elena.

Dr. Elena Rodriguez

Always a pleasure, James.